TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01003275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Two 1 mcg soft gels by mouth daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Two 1 mcg soft gels by mouth daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two soft gels by mouth daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two soft gels by mouth daily for 8 weeks
Study: NCT02289950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab
Description: Farletuzumab will be administered intravenously (IV) weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously (IV) weekly
Study: NCT04654104

Intervention type: OTHER
Intervention: check immune check points
Description: we will evaluate the expression of immune check points

Intervention type: OTHER
Intervention: check immune check points
Description: we will evaluate the expression of immune check points

Intervention type: OTHER
Intervention: check immune check points
Description: we will evaluate the expression of immune check points

Intervention type: OTHER
Intervention: check immune check points
Description: we will evaluate the expression of immune check points
Study: NCT01840189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cortef
Description: Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Solu-cortef
Description: Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months.
Study: NCT01690442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Based HIV/STI Risk Reduction Intervention (CHSR)
Description: The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Renaissance Wellness Promotion (WP)
Description: This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
Study: NCT01643837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Osteopathic Manipulative Light Touch Protocol (LT)
Description: LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
Study: NCT01934296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
Study: NCT05291078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A transcutaneous trigeminal nerve stimulator: High Frequency
Description: 30min/day, at least 5 to 7 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A transcutaneous trigeminal nerve stimulator: Low Frequency
Description: 30min/day, at least 5 to 7 times a week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: A transcutaneous trigeminal nerve stimulator: Sham
Description: 30min/day, at least 5 to 7 times a week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sound Therapy
Description: Notch Therapy at least 30min/day, at least 5 to 7 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound Therapy
Description: Notch Therapy at least 30min/day, at least 5 to 7 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound Therapy
Description: Notch Therapy at least 30min/day, at least 5 to 7 times a week
Study: NCT01586858

Intervention type: OTHER
Intervention: Observational
Description: Observational study of subjects previously enrolled in the RAVE trial
Study: NCT00967538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept 50 mg
Description: All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
Study: NCT01625026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: Obeticholic acid 25 mg/day in three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: Obeticholic acid 25 mg/day in three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to obeticholic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to obeticholic acid
Study: NCT03141203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 10mg vial for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 60mg vial for injection
Study: NCT00855842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: osmotic dilator insertion
Description: osmotic dilators are placed in the cervix to cause cervical dilation
Study: NCT03466957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed applicator
Description: add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
Study: NCT01502566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
Study: NCT01715038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-PLW
Description: Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Child
Description: Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Child
Description: Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA
Description: Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFA
Description: Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA
Description: Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid
Study: NCT01975064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
Study: NCT00237549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optimised treatment
Description: The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls.
Study: NCT03155984

Intervention type: DRUG
Intervention: Anti-CD20 antibody
Description: All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
Study: NCT00950807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: long-acting muscarinic receptor antagonist; 18mcg once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive/ excipients only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573179
Description: GSK573179 investigational drug
Study: NCT06388655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile neurofeedback
Description: The participants were randomly assigned to the MNF active (N=31) or sham control (N=30) groups. The MNF program was administered using a mobile app (equipped with a headset with a 2-channel EEG sensor) for 30 min/day, 3 days/week, for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham mobile neurofeedback
Description: The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
Study: NCT01587222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed.
Study: NCT03395106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent source
Description: Having a parent feature prominently in a news story

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent source
Description: Having a parent feature prominently in a news story

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor source
Description: Having a doctor feature prominently in a news story

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor source
Description: Having a doctor feature prominently in a news story

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative content
Description: News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative content
Description: News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intuitive content
Description: News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intuitive content
Description: News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
Study: NCT03198052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR
Description: CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
Study: NCT00863200

Intervention type: BEHAVIORAL
Intervention: Telephone Intervention
Description: Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.

Intervention type: BEHAVIORAL
Intervention: Questionnaires & Interviews
Description: 3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.

Intervention type: BEHAVIORAL
Intervention: Questionnaires & Interviews
Description: 3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
Study: NCT00003351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT03745274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB04L1
Description: Solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer solution
Study: NCT02037932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
Description: Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
Study: NCT01195727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT01302951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
Study: NCT03919526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/CD22 CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study: NCT03963011

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Ultrasound
Description: Ultrasound imaging of the bowel
Study: NCT03224429

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interviews Decisional Needs Assessment
Description: Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.

Intervention type: OTHER
Group type: OTHER
Intervention: Sickle Cell Decision Aid
Description: Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
Study: NCT00931359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTS-G2 System
Description: Treatment with microwave energy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DTS System (Sham treatment)
Description: Sham treatment - no energy is delivered
Study: NCT02877173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Liposomes for Injection
Description: 3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil Injection
Description: Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
Study: NCT02434848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix
Description: Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years.
Study: NCT04153188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vbeam® Prima System
Description: 3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline HCL 1% Cream
Description: Daily application of Oxymetazoline HCL 1% cream for the 6-month study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL 1% Cream
Description: Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
Study: NCT03801655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-Kult
Description: 4 capsules/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules/day
Study: NCT02369614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 1 Hz rTMS
Description: 1 Hz rTMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 10 Hz rTMS
Description: 10 Hz rTMS

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator:
Description: Sham rTMS
Study: NCT00664833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: The Primary Care Physician (PCP) received the educational intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: The Subject received the educational intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Both the Primary Care Physician (PCP) and the subject received the educational intervention

Intervention type: OTHER
Group type: OTHER
Intervention: No Education
Description: No education provided to either the Primary Care Physician (PCP) or the subject.
Study: NCT03711578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib,
Description: BID, Orally